lucerastat
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT02944487)
Timeline
Indications
Mechanism of action
- Ceramide glucosyltransferaseINHIBITOR
UGCG inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO- Mol. weight
- 219.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1086997 ↗
Also known as
- lucerastat
- lucerastat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03832452 | Phase 1 | Feb 14, 2019 | Idorsia Pharmaceuticals Ltd. |
| NCT03737214 | Phase 3 | Dec 18, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03425539 | Phase 3 | Jun 21, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03380455 | Phase 1 | Jan 9, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT02930655 | Phase 1 | Feb 1, 2015 | Actelion |
| NCT02944474 | Phase 1 | Dec 1, 2003 | Actelion |
| NCT02944487 | Phase 1 | Oct 1, 2002 | Actelion |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | 4 | 4 | 2 | 2018 |
| Actelion | For profit | 3 | 3 | 1 | 2002 |
2 organizations
Page 1 / 1